Javier Milara

Valencia, VC 46014, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 86 publications

Differential modulation of the sGC-cGMP pathway by sGC stimulators and activators in human lung cells.

Differential modulation of the sGC-cGMP pathway by sGC stimulators and activators in human lung cells.

Journal: Biochemical pharmacology

Published: December 12, 2025

Targeting the Keap1-Nrf2 Axis in COPD: Comparative analysis of electrophilic and peptide-based Nrf2 activators in airway and immune cells.

Targeting the Keap1-Nrf2 Axis in COPD: Comparative analysis of electrophilic and peptide-based Nrf2 activators in airway and immune cells.

Journal: European journal of pharmacology

Published: October 23, 2025

Comparative Analysis of Classic and Novel Antitussives on Cough Suppression in Guinea Pigs.

Comparative Analysis of Classic and Novel Antitussives on Cough Suppression in Guinea Pigs.

Journal: Pharmaceutics

Published: September 24, 2025

GTX-11 attenuates lung fibrosis, inflammation and vascular remodeling in preclinical models of lung fibrotic disease.

GTX-11 attenuates lung fibrosis, inflammation and vascular remodeling in preclinical models of lung fibrotic disease.

Journal: Frontiers in pharmacology

Published: July 22, 2025

Immunomodulatory properties of transmembrane mucins: from chronic diseases to cancer.

Immunomodulatory properties of transmembrane mucins: from chronic diseases to cancer.

Journal: Physiological reviews

Published: June 04, 2025

Pharmacological inhibition of Epac1 protects against pulmonary fibrosis by blocking FoxO3a neddylation.

Pharmacological inhibition of Epac1 protects against pulmonary fibrosis by blocking FoxO3a neddylation.

Journal: The European respiratory journal

Published: November 11, 2024

Pharmacological Inhibition of Epac1 Protects against Pulmonary Fibrosis by Blocking FoxO3a Neddylation.

Pharmacological Inhibition of Epac1 Protects against Pulmonary Fibrosis by Blocking FoxO3a Neddylation.

Journal: bioRxiv : the preprint server for biology

Published: September 30, 2024

Phosphodiesterase 4 is overexpressed in human keloids and its inhibition reduces fibroblast activation and skin fibrosis.

Phosphodiesterase 4 is overexpressed in human keloids and its inhibition reduces fibroblast activation and skin fibrosis.

Journal: Chemico-biological interactions

Published: June 15, 2024

Phosphodiesterase 4 is overexpressed in keloid epidermal scars and its inhibition reduces keratinocyte fibrotic alterations.

Phosphodiesterase 4 is overexpressed in keloid epidermal scars and its inhibition reduces keratinocyte fibrotic alterations.

Journal: Molecular medicine (Cambridge, Mass.)

Published: April 23, 2024

Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human.

Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human.

Journal: Vascular pharmacology

Published: January 31, 2024

Pirfenidone and nintedanib attenuates pulmonary artery endothelial and smooth muscle cells transformations induced by IL-11.

Pirfenidone and nintedanib attenuates pulmonary artery endothelial and smooth muscle cells transformations induced by IL-11.

Journal: European journal of pharmacology

Published: November 02, 2023

Targeting IL-11 to reduce fibrocyte circulation and lung accumulation in animal models of pulmonary hypertension-associated lung fibrosis.

Targeting IL-11 to reduce fibrocyte circulation and lung accumulation in animal models of pulmonary hypertension-associated lung fibrosis.

Journal: British journal of pharmacology

Published: October 05, 2023

Showing 1-12 of 86

Last Updated: 09/26/2026